Table 2. Summary of Experimental Studies With Respect to the Role of Different B-Cell Subsets in Atherosclerosis.
| Atherosclerosis Studies in Mice That Involve Different B-Cell Subsets | Effect on Atherosclerosis | B-Cell Subsets (Potentially) Affected |
|||||
|---|---|---|---|---|---|---|---|
| B1a | B1b | IRA | MZ | FO | Bregs | ||
| Adoptive CD19+ B-cell transfer (20×106) into splenectomized or shamoperated Apoe−/− mice22 | ↓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Reconstitution of Ldlr−/− mice with B-cell–deficient (μMT) bone marrow23 | ↑ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| CD20 antibody treatment of Apoe−/− and Ldlr−/− mice24,25 | ↓ | (✓) | ✓ | ? | ✓ | ✓ | ✓ |
| Adoptive transfer of splenic CD43− B cells into lymphocyte-deficient Rag2−/−γ-chain−/−Apoe−/− (5×106 or 5×107) or B-cell–deficient μMT/Apoe−/− (5×106) mice25 | ↑ | … | … | … | ✓ | ✓ | ✓ |
| Adoptive transfer of splenic CD43− B cells (3×107 or 6×107) into B-cell–deficient μMT/Apoe−/− mice28 | ↓ | … | … | … | ✓ | ✓ | ✓ |
| Adoptive transfer of wild-type but not sIgM−/− B1a cells (105 every 3 wk) into splenectomized atherosclerotic Apoe−/− mice29 | ↓ | ✓ | … | … | … | … | … |
| BAFFR-deficient Apoe−/− or Ldlr−/− mice24,30 | ↓ | … | … | (✓) | ✓ | ✓ | ? |
| Anti-BAFFR treatment of Apoe−/− mice31 | ↓ | … | … | (✓) | ✓ | ✓ | ? |
| Reconstitution of Ldlr−/− mice with 50% GM-CSF and 50% B-cell–deficient (μMT) bone marrow to achieve GM-CSF deficiency in B cells only32 | ↓ | … | … | ✓ | … | … | … |
Apoe−/− indicates apolipoprotein E deficient; BAFFR, B-cell–activating factor receptor; Bregs, regulatory B cells; FO, follicular; IRA, innate response activator; Ldlr−/−, low-density lipoprotein receptor; and MZ, marginal zone.